2-naphthol has been researched along with Bowel Diseases, Inflammatory in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beibel, M; Berry, D; Bhuju, S; Dammann, K; Ebner, F; Evstatiev, R; Gasche, C; Khare, V; Kovarik, P; Kuzyk, O; Lang, M; Loy, A; Meisner-Kober, N; Mesteri, I; Passecker, K; Roma, G; Sedlyarov, V | 1 |
| Edsall, RJ; Harris, HA; Henderson, RA; Keith, JC; Manas, ES; Mewshaw, RE; Xu, ZB; Yang, C | 1 |
2 other study(ies) available for 2-naphthol and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis.
Topics: Adenomatous Polyposis Coli; Animals; Apoptosis; Carcinogenesis; Cell Proliferation; Chemokine CCL11; Colorectal Neoplasms; ELAV-Like Protein 1; Feces; Furans; Gastrointestinal Microbiome; HCT116 Cells; Humans; Inflammatory Bowel Diseases; Interleukin-18; Mice; Naphthols; RAW 264.7 Cells | 2017 |
ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.
Topics: Animals; Animals, Genetically Modified; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Estrogen Receptor beta; Female; Genistein; Humans; Inflammatory Bowel Diseases; Ligands; Male; Models, Molecular; Molecular Conformation; Molecular Mimicry; Molecular Structure; Naphthalenes; Naphthols; Organ Size; Rats; Rats, Inbred Lew; Structure-Activity Relationship; Transcription, Genetic; Uterus | 2005 |